Biocrates is the Partner for Metabolic Phenotyping
is an EU funded research project to identify molecular targets for vascular disease treatment.
The collaborative research project sysVASC aims to identify the causative events in cardiovascular diseases in order to predict novel therapeutic targets. The sysVASC consortium includes 17 partners from 10 countries including: 5 SMEs, 4 renowned universities, 4 leading research centres and 3 prominent academic clinical centres.
a large-scale integrating European research project, aims at understanding chronic kidney disease in the context of diabetes and hypertension.
SysKid, which stands for »Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment« – will pave the way for progress in prevention, new diagnostic strategies and treatment options for declining kidney function, which affects millions of patients suffering from diabetes and hypertension.
View related publication...
Impact of Prenatal Stress on brain ageing fetal programming, undernutrition and stressMission: Slowing brain ageing and susceptibility to age-associated diseases: Early programming of pathways and genes and late interventional targets.
stands for Biomarker for Cardiovascular Risk Assessment in Europe. It is a research project co-funded under the the European Unions' Seventh Framework Programme. View related Publication...
NutriTech is a European Commission funded FP7 research project (2012-2015). The goal of NutriTech is to quantify the effect of diet on “phenotypic flexibility”. Phenotypic flexibility extends on metabolic flexibility (the capacity to adapt fuel oxidation to fuel availability) and includes all underlying mechanisms and physiological processes of adaptationwhen homeostasis is challenged.
ADNI - Alzheimer’s Disease Neuroimaging Initiative
ADNI is a global research effort that actively supports the investigation and development of treatments that slow or stop the progression of AD. This multisite, longitudinal study assesses clinical, imaging, genetic and biospecimen biomarkers through the process of normal aging to early mild cognitive impairment (EMCI), to late mild cognitive impairment (LMCI), to dementia or AD.